Snakebite in Australia: pressure-immobilisation and hospital care

Australia is home to some of the world’s most venomous land snakes. Brown snakes (Pseudonaja spp.) cause the majority of deaths; tiger snakes, taipans, death adders, black snakes, mulga snakes, and sea snakes account for most of the remainder. Approximately 3,000 snakebites occur annually across the country, of which around 500 require antivenom treatment and 1–4 prove fatal — a mortality rate that reflects the effectiveness of the pressure-immobilisation technique introduced by Sutherland and colleagues in 1979.

The GP’s role spans three distinct phases: first-aid education (delivered proactively to patients in snake habitat), acute recognition and transfer coordination (for patients who present to or call the practice), and post-discharge follow-up (serum sickness, renal function, mental health, and tetanus status). Hospital emergency departments and toxicologists lead acute antivenom decisions; the GP’s acute contribution is ensuring the patient arrives in hospital with the pressure bandage intact and with maximum time before systemic envenomation takes hold.

A. Core clinical — the AU general-practice framework

Envenomation syndromes

Australian elapid venoms produce five main clinical syndromes, frequently in combination. Knowing which syndrome to expect from which species guides observation and antivenom choice:

Syndrome	Mechanism	Common species
VICC (venom-induced consumption coagulopathy)	Procoagulant venom consumes fibrinogen → INR ↑↑, fibrinogen ↓, D-dimer ↑↑	Brown, tiger, taipan, rough-scaled
Anticoagulant coagulopathy	Phospholipase A₂ → isolated APTT prolongation	Black snake, mulga
Neurotoxicity	Pre- or post-synaptic blockade → ptosis → descending flaccid paralysis	Tiger, taipan, death adder, sea snake
Myotoxicity	Direct muscle necrosis → myalgia, rising CK, myoglobinuria, AKI	Tiger, mulga, rough-scaled, sea snakes
Thrombotic microangiopathy (TMA)	MAHA + thrombocytopaenia + AKI (may present weeks later)	Brown, tiger

Brown snake bites can produce severe VICC with minimal local pain — patients may collapse within minutes from cardiac arrest or intracranial haemorrhage. The absence of a visible puncture wound or local swelling does not exclude life-threatening envenomation.

Epidemiology and risk profile

Higher-risk groups include rural and remote workers, herpetologists, defence and emergency personnel, and anyone in outdoor recreational settings during summer. Alcohol involvement is common. Bites peak between October and March, and males aged 20–60 are disproportionately represented (Isbister Med J Aust 2013). Approximately 50% of brown snake bites and 70% of tiger snake bites are dry bites with no envenomation — but this cannot be determined at the scene.

Focused history

For a patient who has been bitten or suspects a bite:

• Time of bite — the 12-hour minimum observation period is counted from the bite, not from hospital arrival.
• Geographic location — determines probable species and antivenom strategy. Tasmania is the only state where tiger snake is the sole dangerous species, making antivenom selection straightforward.
• First aid applied — when the bandage went on and whether the limb is immobilised; delays accelerate lymphatic spread.
• Symptoms — nausea, vomiting, headache, abdominal pain, sweating, blurred or double vision, drooping eyelid (ptosis), limb weakness, bleeding from gums, dark urine, or collapse.
• Past antivenom exposure — sensitisation increases anaphylaxis risk; document batch number and any previous reaction.
• Never instruct the patient or bystanders to capture, approach, or photograph the snake.

Examination and monitoring

Key examination priorities:

• Vital signs with continuous ECG monitoring (brown snake VICC carries cardiac arrest risk).
• Respiratory effort: ask the patient to count to 25 in a single breath. An inability to reach 25 indicates impending respiratory failure from neurotoxicity.
• Bite site: fang marks may be single, paired, or invisible. Do not wash the wound — residual venom on the skin is essential for Snake Venom Detection Kit (SVDK) analysis in hospital.
• Cranial nerves: ptosis is the earliest neurotoxicity sign — test with the patient attempting to open the eyes fully while looking upward.
• Bandage check: confirm firm pressure without arterial occlusion; capillary return must be present distal to the bandage.

Pressure-immobilisation technique — the critical skill

The Australian Resuscitation Council Guideline 9.4.8 mandates pressure-immobilisation for all suspected Australian venomous snake bites, funnel-web spider bites, blue-ringed octopus contacts, and cone snail stings. The technique blocks lymphatic flow — the dominant route for elapid venom transit before systemic entry — without compromising arterial or venous circulation (Sutherland Lancet 1979).

Correct application — step by step:

1. Lay the patient down immediately. Reassure and instruct them not to move.
2. Apply a broad (10–15 cm) elasticated bandage directly over the bite site — not above or below it, but starting at the bite.
3. Bandage the entire limb outward from the bite: for a lower-limb bite, bandage from toes to groin; for an upper-limb bite, from fingers to axilla.
4. Firmness should approximate wrapping a badly sprained ankle — approximately 50–70 mmHg. A finger should not slip easily under the bandage.
5. Mark the bite site on the outside of the bandage with a pen.
6. Splint the limb (improvised if necessary: branch, magazine, umbrella) and immobilise with a sling or cling-wrap. Muscle pump activity drives lymphatic propulsion; the limb must be mechanically immobilised.
7. The patient must not walk if a lower limb is bitten.
8. Call 000. The bandage and splint stay on until the patient is in hospital with antivenom drawn up at the bedside.

For bites on the face, neck, or trunk, full-limb pressure-immobilisation is not feasible — apply firm direct pressure over the bite site as best as possible.

First-aid interventions to actively avoid

These approaches are harmful or ineffective and must be explicitly taught against in any snakebite education:

• Sucking the wound — removes no venom; introduces infection.
• Cutting or incising — no benefit; increases bleeding risk in VICC.
• Tourniquet — causes ischaemia; masks ongoing envenomation; sudden release is dangerous.
• Ice or cold packs — no evidence of benefit; tissue damage risk.
• Suction devices (marketed pump extractors) — no clinical evidence; delay correct first aid.
• Electric shock therapy — no evidence; potential for harm.
• Washing the bite site — destroys residual venom needed for SVDK identification.
• Alcohol — vasodilates and may accelerate absorption.

---

B. Evidence appraisal — what the trials tell us

The physiology behind pressure-immobilisation

Sutherland’s 1979 Lancet paper established in animal models that elapid venom travels from the bite site via the lymphatic system before entering the venous circulation. Approximately 55 mmHg of sustained subcutaneous pressure prevents lymph flow; concurrent limb immobilisation removes the muscle-pump contribution to lymphatic propulsion. Human randomised trial data are ethically impossible to obtain, but the technique has underpinned Australian Resuscitation Council and eTG complete guidance for over 45 years. Real-world variability in bandage application quality is a recognised limitation — first-aid training workshops with mannequin practice produce better application than leaflet distribution alone.

Antivenom dosing — the ATTRACT trial

The ATTRACT randomised controlled trial (Isbister 2013) compared single-vial versus multiple-vial brown snake antivenom for VICC. A single vial was non-inferior to larger doses for time to coagulopathy recovery and clinical outcomes. Current guidance is one vial as the initial dose for most envenomations, with a second vial given if coagulopathy persists or systemic envenomation is inadequately controlled after the first infusion.

Premedication before antivenom — evidence against

Routine pre-treatment with adrenaline, antihistamines, or corticosteroids before antivenom infusion was historically advocated to prevent anaphylaxis (antivenom is a heterologous animal-derived protein with approximately 5% hypersensitivity rate). Isbister (NEJM 2008) and a subsequent Lancet Infectious Diseases study (Isbister 2013) showed premedication did not reduce the rate of antivenom hypersensitivity reactions. Current practice: have adrenaline drawn up and ready at the bedside; do not routinely premedicate. Antivenom infusion should occur only in a setting with resuscitation capability.

SVDK accuracy and limitations

The Snake Venom Detection Kit uses an ELISA swab of the unwashed bite site against five venom groups. A positive result guides monovalent antivenom choice, reducing protein load and potentially adverse reaction risk. Nimorakiotakis and Winkel (EMA 2003) reported false-positive rates of 5–10% and reduced sensitivity with washed wounds. A negative SVDK does not exclude envenomation — if clinical or biochemical envenomation is present and the SVDK is negative or unavailable, polyvalent antivenom or geographically-guided monovalent antivenom should be given without further delay.

FFP for brown-snake VICC

Brown snake VICC produces profound consumption of fibrinogen and clotting factors. Whether to give fresh frozen plasma (FFP) alongside antivenom remains debated. ATTRACT trial data suggested FFP may accelerate coagulation normalisation but showed no mortality or morbidity benefit. For VICC without active bleeding, antivenom and supportive monitoring is the default; FFP is added for INR >3 persisting after antivenom, or for active bleeding (intracranial haemorrhage). Vitamin K does not correct VICC — the coagulopathy is consumptive, not vitamin-K-dependent, and adding Vitamin K does not accelerate recovery.

---

C. Hospital workflow and antivenom selection

SVDK-guided versus geographic antivenom selection

When the SVDK is positive and geographically plausible, the corresponding monovalent antivenom is preferred. When the SVDK is unavailable, negative in the presence of confirmed clinical envenomation, or results are delayed:

• Tasmania only: tiger snake antivenom (the sole dangerous species; this simplifies management considerably).
• All other mainland states and territories: polyvalent antivenom (covers all five mainland groups) or geographically guided monovalent antivenom if local species probability is high.

Antivenom is given only for confirmed systemic envenomation — biochemical (abnormal INR, low fibrinogen, elevated D-dimer, rising CK, thrombocytopaenia) or clinical (collapse, neurotoxicity, cardiac arrest, AKI from envenomation). Prophylactic antivenom is not supported by evidence and carries its own anaphylaxis risk (Isbister Med J Aust 2017).

Serial blood monitoring — the observation protocol

Blood tests at presentation, one hour, six hours, and twelve hours post-bite are the cornerstone of the hospital observation protocol. Tests include coagulation screen (INR, APTT, fibrinogen, D-dimer), full blood count and film (for thrombocytopaenia and schistocytes indicating TMA), U&E and creatinine (AKI), CK (myotoxicity), and ECG (brown snake cardiotoxicity). If all parameters are normal at 12 hours and the patient is asymptomatic, discharge with safety-netting is appropriate. Confirmed envenomation warrants a minimum 48-hour admission.

Serum sickness and delayed TMA — post-discharge watch points

Serum sickness — a type III immune reaction to heterologous antivenom protein — typically presents 5–14 days after antivenom infusion with fever, rash, arthralgia, and lymphadenopathy. Treatment is a brief course of prednisolone (0.5–1 mg/kg for 5–7 days). Thrombotic microangiopathy (TMA) may present weeks after the initial bite with haemolytic anaemia, thrombocytopaenia, and rising creatinine. Monitoring full blood count, U&E, and urinalysis at one- and four-week GP reviews detects this late but serious complication.

---

D. Australian operations

MBS items applicable in general practice

For GP-led acute coordination and post-discharge management:

• Standard consultation (items 23 / 36 / 44) — initial assessment or post-discharge review.
• Urgent or after-hours home visit (items 19 / 20; after-hours items 597–600) — rural or remote call-out.
• ECG (item 11707).
• Telehealth (items 91890 / 91891) — post-discharge follow-up only; acute snakebite assessment requires face-to-face examination.
• Mental Health Care Plan (items 2715 / 2717) — post-traumatic stress following the event.
• Aboriginal and Torres Strait Islander Health Assessment (item 715) — for eligible patients in remote communities.

Antivenom access — not on the PBS

Antivenom for Australian snake species is manufactured by CSL Seqirus and distributed nationally through Lifeblood to approved hospital stocking sites. It is not a PBS prescription item — it is supplied free to hospitals through the National Snake Antivenom Stock program and is never administered in a GP setting. GPs in remote areas may hold emergency antivenom through Doctor’s Bag provisions or RFDS protocols; coordinate with the local health district for eligibility and cold-chain storage requirements.

RFDS coordination and the Poisons Information Centre

For rural and remote patients, time to hospital is the critical variable. Contact the Royal Flying Doctor Service and the Poisons Information Centre (13 11 26 — available 24/7 across Australia) simultaneously. The Poisons Information Centre connects clinicians in real time with a clinical toxicologist who can provide guidance on pressure-immobilisation, antivenom indication, and retrieval priorities. Maintaining the pressure bandage during extended RFDS retrieval times is the single greatest modifiable factor in remote snakebite outcomes.

Occupational, medico-legal, and reporting obligations

Snakebite in an occupational context qualifies for workers’ compensation — document the time, location, activity, and snake description precisely. Envenomation deaths are reportable to the State Coroner. Snakebite is not a notifiable disease, but the AVRU collects national data and clinician contributions are welcomed. Clear documentation of antivenom vial batch number and patient response is essential for future anaphylaxis risk assessment.

---

E. Special populations

Aboriginal and Torres Strait Islander communities in remote areas

Snakebite risk is elevated in remote and very remote communities where proximity to snake habitat, outdoor-work patterns, and prolonged transport times to definitive care converge. Apply a lower threshold for RFDS retrieval. Coordinate with the local Aboriginal Community Controlled Health Organisation (ACCHO) and RFDS for culturally safe communication during acute care. Closing the Gap PBS Co-payment arrangements apply to any post-discharge medications prescribed. Tetanus booster status may be incomplete — check and update per the Australian Immunisation Handbook.

Children

Children sustain bites disproportionately during outdoor play. Venom dose is body-weight-independent — children receive the same absolute venom volume as adults but at a higher weight-adjusted dose. Antivenom dosing in children is the same as for adults (one vial initially, regardless of body weight) — this is counterintuitive but pharmacokinetically established. Paediatric cases with confirmed neurotoxicity or severe coagulopathy should be directed to a facility with paediatric intensive care capability.

Sea snakes and aquatic envenomation

Sea snake bites occur primarily in aquatic occupational settings — commercial divers, prawn fishermen — and occasionally among recreational swimmers in tropical northern waters. The venom produces predominantly neurotoxicity and myotoxicity with minimal local reaction. Pressure-immobilisation applies. Sea snake antivenom (CSL Seqirus) or tiger snake antivenom (cross-reactive) is the treatment of choice; haemodialysis may be needed for severe myoglobin-driven AKI. A swimmer who develops ptosis, weakness, or dark urine hours after ocean activity warrants urgent blood tests and consideration of sea snake envenomation.

---

When to escalate

Every suspected snakebite must go directly to hospital — without exception. There is no GP-manageable snakebite; the treatment setting is always a hospital emergency department.

If a patient presents to the practice after a bite:

• Keep them still and do not remove the bandage.
• Call 000 immediately.
• Contact the Poisons Information Centre 13 11 26 (24/7 AU-wide) for real-time toxicologist guidance while awaiting transfer.
• Prepare the current medication list and document any previous antivenom exposure or allergy.

Dry bites (approximately 50% of brown snake bites) cannot be distinguished from envenomation at the scene — all suspected bites require the full 12-hour observation.

Post-discharge GP review triggers for urgent re-referral:

• Rash, fever, or arthralgia within 14 days of antivenom (serum sickness).
• Falling platelet count, rising creatinine, or red-cell fragments on blood film (TMA).
• Progressive muscle weakness or declining renal function.
• Symptoms consistent with post-traumatic stress disorder — intrusive memories, hyperarousal, avoidance of outdoor activities.

---

What this article is and is not

This article supports clinical education for Australian general practice and patient awareness via HealthDirect. It does not replace clinical judgement, specialist consultation, or real-time toxicologist advice from the Poisons Information Centre (13 11 26). Snakebite management guidelines are updated by the Australian Resuscitation Council and the AVRU — check these sources for the most current protocols. No outcome of any individual patient can be predicted or guaranteed. This content was authored by Dr Hoe Bing Lo (MBBS, FACRRM, AHPRA MED0001212640) for educational purposes and has not yet completed the formal AHPRA clinical review process (ahpraReviewed: false).

---

Sources cited

• Australian Resuscitation Council — Guideline 9.4.8 Envenomation
• Australian Venom Research Unit (AVRU)
• eTG complete — Bites and stings
• HealthDirect — Snakebite
• Australian Immunisation Handbook — ATAGI
• Royal Flying Doctor Service
• Isbister GK et al. Australian snakebite epidemiology. Med J Aust 2013
• Isbister GK et al. ATTRACT trial — single-vial antivenom for brown snake VICC. Crit Care Med 2013
• Isbister GK. Antivenom premedication. NEJM 2008
• Isbister GK et al. Adverse reactions to snake antivenom. Lancet ID 2013
• Isbister GK. Antivenom timing and outcome. Med J Aust 2017
• Sutherland SK et al. Pressure-immobilisation technique. Lancet 1979
• Nimorakiotakis B, Winkel KD. SVDK accuracy. EMA 2003
• Poisons Information Centre Australia — 13 11 26 (24/7)